Last reviewed · How we verify

NCT04597099: CRM010

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

Status unknown EARLY_PHASE1 Last updated 2 November 2023
What this trial tests

EARLY_PHASE1 trial testing Micronized progesterone in PCOS in 10 participants. Status unknown.

Timeline
26 October 2022
Primary endpoint
1 October 2025
1 October 2025

Quick facts

Lead sponsorUniversity of Virginia
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposebasic science
Enrollment10
Start date26 October 2022
Primary completion1 October 2025
Estimated completion1 October 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Virginia

Who can join

Adults 18 to 30, female only, with PCOS or Polycystic Ovary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is trying to find out if flutamide (a medication that blocks the effects of testosterone) may help normalize an aspect of pituitary function (specifically, gonadotropin surge generation) in PCOS. This is a randomized, placebo-controlled, double-blinded, crossover study. The investigators hypothesize that in estradiol-pretreated women with PCOS, acute progesterone augmentation of FSH release (positive feedback) will be enhanced by flutamide.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Micronized progesterone

Trials testing the same drug.

Other recruiting trials for PCOS

Currently open trials in the same condition.

Other University of Virginia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04597099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing